Acorda Therapeutics

American biotechnology company

Acorda Therapeutics is an American biotechnology company that develops therapies for neurological disorders. The company is headquartered in Ardsley, New York.

History

Acorda Therapeutics was founded in 1995 by Ron Cohen, M.D., with the goal of developing therapies to restore function and improve the lives of people with neurological disorders. The company initially focused on developing treatments for spinal cord injury and multiple sclerosis (MS).

Products

Acorda Therapeutics has developed several products, including:

• Ampyra (dalfampridine) - A medication approved by the Food and Drug Administration (FDA) to improve walking in patients with multiple sclerosis. It is a potassium channel blocker that enhances conduction in demyelinated nerves.

• Inbrija (levodopa inhalation powder) - An inhaled form of levodopa for the treatment of Parkinson's disease symptoms. It is used as an "on-demand" therapy to manage "off" episodes in patients already taking a carbidopa/levodopa regimen.

Research and Development

Acorda Therapeutics is involved in ongoing research and development efforts to create new therapies for neurological conditions. The company's research focuses on areas such as neuroprotection, neuroregeneration, and neuroplasticity.

Corporate Structure

Acorda Therapeutics operates as a publicly traded company on the NASDAQ stock exchange under the ticker symbol "ACOR." The company is led by a team of executives with expertise in biotechnology and pharmaceuticals.

Community Involvement

Acorda Therapeutics is committed to supporting the neurological community through various initiatives, including patient advocacy, education, and outreach programs. The company collaborates with patient organizations and healthcare professionals to improve patient care and access to therapies.

Related pages

• Biotechnology
• Neurology
• Multiple sclerosis
• Parkinson's disease

Gallery

• 
  Acorda Therapeutics logo